Big Pharma is transforming right in front of our eyes and in the not too distant future, you may not recognize it. In fact, the next blockbuster treatment may not be a drug at all, but rather an electroceutical.
For over a century, medicine has centered on chemistry and biology to treat disease. However, that is rapidly changing toward the use devices that are capable of speaking the body’s electric language to treat human ailments and diseases. This new age of medicine is commonly referred to as “Bioelectronic Medicine,” and it seeks to use electroceuticals rather than drugs to treat disease.
Big Pharma has recognizes the potential of electroceuticals and has begun to invest heavily in this new field of medicine.
For example, GlaxoSmithKline has teamed up with Google’s parent company to form a $715 million joint venture called Galvani Bioelectronics to develop and commercialize electroceutical products.
Merck & Co. invested in a non-invasive vagus nerve stimulator (VNS) to treat migraine headaches. Novartis is developing a smart contact-lens that will allow diabetics to monitor themselves continuously by measuring the glucose level in their tears; and Johnson & Johnson (J&J) has invested in an implantable electroceutical for treating heart failure.
One company that investors interested in biotech should take note of is Endonovo Therapeutics, Inc. (ENDV). It recently announced that it had signed a term sheet to raise $5 million from a strategic healthcare investor, as part of a larger $15 million round of financing to uplist the company onto a national stock exchange and to develop a pipeline targeting vascular diseases and ischemia/reperfusion injuries using its non-invasive electroceutical. ENDV’s non-invasive technology, which it calls “Immunotronics”, uses time variant magnetic pulses to control the inflammatory response and promote the formation of new blood vessels.
Some of the conditions that ENDV is targeting include ischemic stroke, myocardial infarction, peripheral artery disease, as well as ischemia/reperfusion injury in the liver and kidneys.
The life threatening and debilitating conditions that Endonovo is seeking to treat are among the largest with clinical unmet needs. For example, between 2012 and 2030, total direct medical stroke-related costs are projected to triple, from $71.6 billion to $184.1 billion, with the majority of the projected increase in costs arising from patients 65 to 79 years of age. Furthermore, over 6.8 million Americans are estimated to have peripheral artery disease, according to the American Heart Association.
So should investors be bullish on electroceuticals as well?
The bottom line is that as strategic investors, you will be looking at the magnitude of the opportunity at hand and assessing the level of risk involved. In biotech, investors always tend to have huge appetites for high risks due to the potential payout that could come once a product reaches the market.
With its non-invasive approach, large potential opportunity in vascular diseases/ischemia and a valuation that is hovering just above its 52 week low, ENDV is a company that presents a potentially favorable risk/reward profile for biotech investors concentrated on growth.
A few other biotech stocks that are drawing investor interest include:
Regulus Therapeutics, Inc. (RGLS) should make some big new Tuesday. The biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced that it will host a R&D day on Tuesday, December 6, 2016 from 8:30 a.m. to 11:30 a.m. EST in New York City where it plans to announce new development candidates. Members of the Regulus management team will also provide a broader pipeline update with additional perspective from three external medical and scientific experts collaborating with the company.
Arbutus Biopharma Corporation (ABUS) a biopharmaceutical company, has seen the Zacks Consensus Estimate for its current year earnings soaring 19.3% over the last 30 days.
Eyegate Pharmaceuticals, Inc. (EYEG) shares rose about 10% on Monday after the company announced promising data from its mid-stage trial of its leading product candidate. Specifically, the data came from EyeGate’s third stage of its Phase 1b/2a trial of iontophoretic EGP-437 for the treatment of ocular inflammation and pain in post-surgical cataract patients.
Dynavax Technologies, Corp. (DVAX) is scheduled to have its PDUFA hearing date on December 15, 2016 for its Heplisav-B drug for the treatment of hepatitis B. Shares of Dynavax were trading up over 5% at $4.95. The consensus price target is $22.00, and the 52-week range is $3.20 to $29.86.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.
Distributed by In2town Public Relations
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States